ArticleFrontiers in aging neuroscience2025
Molecular targets of neuroplasticity in ischemic stroke: insights from GEO database, single-cell analysis and immune infiltration analysis.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanisms, Biomarkers, and Therapeutic Interventions of Neuroplasticity After Ischemic Stroke-A Scoping Review.Brain sciences · 2026Review
- Microglia and neuroinflammation: function, heterogeneity, and crosstalk.Cellular & molecular immunology · 2026Review
- Identification and validation of the potential therapeutic value of CASK in osteosarcoma: a computational analysis andFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study is aimed to identify diagnostic and therapeutic biomarkers related to neuroplasticity in IS. Gene expression profiling (GSE61616) was derived from GEO, and neuroplasticity-related genes were obtained from the GeneCards databases. The overlapping genes related to neuroplasticity were processed for GO and KEGG analysis. The protein interaction network and hub genes were identified using Cytoscape and the PPI network. Then we predicted the potential TFs and miRNAs related to hub genes. Single-cell analysis was performed to explore cellular localization and intercellular communications related to hub genes in GSE167593. Immune infiltration characteristics were explored via GSVA package. The correlation between various immune cells and hub genes (CCR5 and CXCR4) was calculated via linKET package. Finally, DGIdb database was used for screening small-molecule drugs of CCR5 and CXCR4. Our study screened five significant neuroplasticity-related hub genes (CCR5, CXCR4, TIMP1, GRIN1, and GRM1). Moreover, single-cell analysis revealed that the CCR5 was specifically expressed in microglia and macrophages, while the CXCR4 was specifically expressed in T cells, NK cells, macrophages, and granulocytes. Immune infiltration and correlation analysis revealed a positive association of CCR5 with aDCs and T helper cells, while CXCR4 was positively correlated with CD8+ T cells, but negatively correlated with Tfh. Finally, the Leronlimab, Ulocuplumab, Burixafor, and MSX-122 are promising drugs to treat IS via targeting on CCR5 and CXCR4. In conclusion, our findings suggest that CCR5 and CXCR4 are promising targets for enhancing neuroplasticity post-ischemic stroke, thus providing potentially effective and reliable therapeutic targets for future interventional strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.